QUICK & CONCISE. EARLY & ACTIONABLE.

The FIRST AND ONLY therapy selection panel designed specifically for your early-stage NSCLC patients. Personalized oncology intervention immediately after an early-stage diagnosis is possible – but it requires the full picture.

The Early-stage NSCLC Panel offers testing for relevant biomarkers in early-stage NSCLC.

Precise profiling. Expert analysis. Complete results.

Brought to you by the market leader in Heme Cancer Testing for over 20 years.
Neo Comprehensive™ – Heme Cancers analyzes 433 genes associated with most hematologic malignancies from myeloid and lymphoid lineages to detect DNA and RNA alterations in one assay.

Precision Oncology: SIMPLER, BETTER, FASTER

Neo Comprehensive – Solid Tumor covers 517 cancer relevant genes with MSI/TMB using DNA and RNA to detect SNVs, Indels, CNVs, fusions and splice variants in a single NGS assay. Results delivered in 10 days. 

RaDaR delivers personalized detection of minimal residual disease (MRD) and recurrence, with a simple blood draw. RaDaR MRD testing is validated for use in multiple solid tumor cancers including breast, colorectal, lung and head & neck.

Neo Comprehensive Myeloid Disorders is a DNA & RNA next-generation sequencing (NGS) comprehensive genomic profile (CGP) analyzing 164 genes relevant in myeloid neoplasms for diagnostic evaluation, prognosis, risk stratification, and therapy guidance.

NeoTYPE® DNA & RNA – Lung is a targeted tissue-based assay featuring RNA-based fusion detection. Results delivered in only 10 days along with a simple, easy to interpret report.